Last reviewed · How we verify
naratriptan HCl
Naratriptan selectively binds to serotonin 5-HT1B/1D receptors on cranial blood vessels and nerve terminals to constrict blood vessels and inhibit neuropeptide release, thereby relieving migraine headaches.
Naratriptan selectively binds to serotonin 5-HT1B/1D receptors on cranial blood vessels and nerve terminals to constrict blood vessels and inhibit neuropeptide release, thereby relieving migraine headaches. Used for Acute treatment of migraine with or without aura in adults.
At a glance
| Generic name | naratriptan HCl |
|---|---|
| Also known as | Amerge |
| Sponsor | Cady, Roger, M.D. |
| Drug class | Triptan (5-HT1B/1D receptor agonist) |
| Target | 5-HT1B receptor, 5-HT1D receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
As a triptan, naratriptan is a selective serotonin 5-HT1B/1D receptor agonist that acts on intracranial blood vessels to cause vasoconstriction and reduce the inflammatory cascade associated with migraine. It also inhibits the release of vasoactive neuropeptides from trigeminal nerve terminals, providing dual anti-migraine effects through both vascular and neuronal mechanisms.
Approved indications
- Acute treatment of migraine with or without aura in adults
Common side effects
- Chest pain or pressure
- Dizziness
- Drowsiness
- Paresthesia
- Nausea
- Fatigue
Key clinical trials
- Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fed Conditions (NA)
- Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fasted Conditions (NA)
- Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet
- Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- naratriptan HCl CI brief — competitive landscape report
- naratriptan HCl updates RSS · CI watch RSS
- Cady, Roger, M.D. portfolio CI